From: Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
B6H12
HuNb1-IgG4
Binding effect (EC50)
1.948Ā Ī¼g/mL
0.868Ā Ī¼g/mL
Blocking effect (IC50)
12.341Ā Ī¼g/mL
1.509Ā Ī¼g/mL
Affinity (KD)
7.81Eā09Ā M
4.85Eā09Ā M